Digestive and Liver Disease最新文献

Full Title Page /Editorial Board 完整的标题页/编辑委员会

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-04-25 DOI: 10.1016/S1590-8658(25)00717-0

引用次数: 0

Neurogastroenterology: The Cinderella among the ecological niches of gastroenterology? 神经胃肠病学：胃肠病学生态位中的灰姑娘？

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-04-07 DOI: 10.1016/j.dld.2025.03.011

Gabrio Bassotti, Christian Lambiase, Francesca Galeazzi, Massimo Bellini

{"title":"Neurogastroenterology: The Cinderella among the ecological niches of gastroenterology?","authors":"Gabrio Bassotti, Christian Lambiase, Francesca Galeazzi, Massimo Bellini","doi":"10.1016/j.dld.2025.03.011","DOIUrl":"https://doi.org/10.1016/j.dld.2025.03.011","url":null,"abstract":"Neurogastroenterology (NGE) refers to a specific sub-specialty of gastroenterology that investigates the pathophysiology, diagnostics and therapeutic approaches to the \"disorders of gut-brain interaction\" (DGBIs), frequently encountered in clinical practice and often associated with poor quality of life and high healthcare costs. Two recent national surveys, focused on common DGBIs, highlighted two main issues. Despite the high incidence of DGBIs there is a lack of awareness and appropriate training to effectively treat these conditions and a lack of specific referral centers in each region. Indeed, specific training and a multidisciplinary approach are required to properly manage these patients, but these are not always available. As a result, NGE lacks attractiveness for many young gastroenterologists. We believe that NGE has great potential to emerge among the various sub-branches of gastroenterology. However, its growth is limited by lack of specific training, knowledge, accessibility, diagnostic capabilities, multidisciplinary integration, and financial investments in research. To bridge this gap, it would be helpful to overcome these limits through an increase in specific training concerning DGBIs among students, residents, physicians and general practitioners. This, coupled with improved access to advanced diagnostic tests, innovative therapies, and a better multidisciplinary approach, could help expand the knowledge in this still niche area and achieve better treatment outcomes for patients.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness and safety of intravenous lidocaine in the analgesic management of acute pancreatitis: A retrospective study. 静脉注射利多卡因镇痛治疗急性胰腺炎的有效性和安全性：一项回顾性研究。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-04-05 DOI: 10.1016/j.dld.2025.03.025

Louise Ghilardi, Paul Tarpin, Ottilie Trocheris-Fumery, Franck Brazier, Sami Hakim, Mathurin Fumery, Clara Yzet

{"title":"Effectiveness and safety of intravenous lidocaine in the analgesic management of acute pancreatitis: A retrospective study.","authors":"Louise Ghilardi, Paul Tarpin, Ottilie Trocheris-Fumery, Franck Brazier, Sami Hakim, Mathurin Fumery, Clara Yzet","doi":"10.1016/j.dld.2025.03.025","DOIUrl":"https://doi.org/10.1016/j.dld.2025.03.025","url":null,"abstract":"Introduction: Intravenous (IV) lidocaine has both analgesic and anti-inflammatory effects. Its use has never been evaluated for analgesia for patients with acute pancreatitis (AP). We aimed to evaluate the effectiveness and safety of IV lidocaine in the management of AP resistant to weak opioids.Materials and methods: We conducted a retrospective, monocentric study between January 2015 and December 2021 that included consecutive patients with (i) AP and (ii) pain resistant to non-opioid and weak-opioid analgesia (tramadol) (iii) treated with IV lidocaine. The effectiveness of the treatment was defined as a decrease in the numerical pain scale (NPS) of at least one point from the initiation of lidocaine and the absence of a need for opioid analgesia (morphine or oxycodone).Results: In total, 154 patients were included. The patients were predominantly male (69 %), with a median age of 48.5 years [37.0; 58.0]. The main etiology of AP was alcoholic (36 %), and necrotizing AP was observed for 69 % of patients. Lidocaine was continuously administered at a dose of 2 g/24 h. Lidocaine treatment was effective for 88.3 % of patients (136/154). The median score on the NPS before the administration of lidocaine was 8.0 [7.0; 9.0] and significantly decreased to 5.8 [4.5; 7.0] by day 1 (p < 0.001). No factors were associated with lidocaine failure. Two (1.3 %) patients experienced lidocaine-related adverse events, including skin rash and dysgeusia, and no severe adverse events were observed.Conclusion: IV lidocaine administration appears to be effective and safe for patients with AP with pain resistant to weak-opioid analgesia. Further prospective studies are needed to confirm these results.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus. 欧洲克罗恩结肠炎组织护理质量标准对意大利的适应：意大利炎症性肠病研究小组的共识。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-04-05 DOI: 10.1016/j.dld.2025.03.010

Gionata Fiorino, Flavio Andrea Caprioli, Sara Onali, Fabio Salvatore Macaluso, Cristina Bezzio, Franco Armelao, Alessandro Armuzzi, Monia Baldoni, Giorgia Bodini, Fabiana Castiglione, Marco Daperno, Stefano Festa, Federica Furfaro, Paolo Gionchetti, Salvatore Leone, Gaetano Luglio, Monica Milla, Giammarco Mocci, Daniele Napolitano, Ambrogio Orlando, Enrica Previtali, Daniela Pugliese, Sara Renna, Antonio Rispo, Simone Saibeni, Gianluca Sampietro, Edoardo Savarino, Franco Scaldaferri, Rocco Spagnuolo, Angela Variola, Anna Viola, Angelo Viscido, Giovanna Vitale, Debora Zaetta, Fabiana Zingone, Agostino Colli, Massimo Claudio Fantini

{"title":"Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus.","authors":"Gionata Fiorino, Flavio Andrea Caprioli, Sara Onali, Fabio Salvatore Macaluso, Cristina Bezzio, Franco Armelao, Alessandro Armuzzi, Monia Baldoni, Giorgia Bodini, Fabiana Castiglione, Marco Daperno, Stefano Festa, Federica Furfaro, Paolo Gionchetti, Salvatore Leone, Gaetano Luglio, Monica Milla, Giammarco Mocci, Daniele Napolitano, Ambrogio Orlando, Enrica Previtali, Daniela Pugliese, Sara Renna, Antonio Rispo, Simone Saibeni, Gianluca Sampietro, Edoardo Savarino, Franco Scaldaferri, Rocco Spagnuolo, Angela Variola, Anna Viola, Angelo Viscido, Giovanna Vitale, Debora Zaetta, Fabiana Zingone, Agostino Colli, Massimo Claudio Fantini","doi":"10.1016/j.dld.2025.03.010","DOIUrl":"https://doi.org/10.1016/j.dld.2025.03.010","url":null,"abstract":"Introduction: Inflammatory bowel disease (IBD) poses significant clinical challenges due to its chronic, disabling nature. Despite established guidelines, care standards remain inconsistent globally. In 2020, the European Crohn's Colitis Organisation (ECCO) developed quality-of-care standards. The Italian Group for the Study of IBD (IG-IBD) aimed to adapt those recommendations to Italy.Methods: A 42-member interdisciplinary panel used a Delphi consensus to evaluate and modify ECCO statements and levels of importance, incorporating patient representatives and regional experts. Those statements were revised, some missing statements were added, and a two-round voting session was held among participants. Agreement ≥80 % was needed to approve a statement.Results: From 101 ECCO statements, 112 tailored criteria were developed. In comparison to the ECCO statements, 80 were confirmed with the same level of importance, 9 were confirmed with different levels of importance, 9 points were merged in a broader statement, 3 points were dropped out during the two voting rounds, and 12 were added as new points.Conclusion: The adapted standards provide a framework for standardizing IBD care in Italy. This model might help other countries in aligning with ECCO standards.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author's Reply: "From Data to practice: The necessity of optimizing ustekinumab treatment strategies". 作者回复：“从数据到实践：优化ustekinumab治疗策略的必要性”。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-04-05 DOI: 10.1016/j.dld.2025.03.020

Zhaopeng Huang, Lang Lin, Kang Chao, Jian Tang

引用次数: 0

Comments on "Establishing a nomogram for predicting necrotizing enterocolitis in premature infants: A retrospective multicenter cohort study". “建立预测早产儿坏死性小肠结肠炎的nomogram：一项回顾性多中心队列研究”。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-04-05 DOI: 10.1016/j.dld.2025.03.016

Muhammad Hamza Butt, Zain Ul Abideen, Muhammad Adeel Ashraf, Muhammad Jan

引用次数: 0

Optimization of ustekinumab dosing in Crohn's disease: Addressing variability in treatment strategies and dosing evaluation. 克罗恩病ustekinumab剂量的优化：解决治疗策略和剂量评估的变异性

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-04-02 DOI: 10.1016/j.dld.2025.03.005

Shuyuan Wang, Lingkang Wu

引用次数: 0

Author's Reply: "Comment on: Aetiology-specific inflammation patterns in patients and rat models of compensated cirrhosis". 作者回复：“代偿性肝硬化患者和大鼠模型中病因特异性炎症模式的评论”。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-04-02 DOI: 10.1016/j.dld.2025.03.018

Benedikt Silvester Hofer, Thomas Reiberger

引用次数: 0

BOC.02.1 DIAGNOSTIC YIELD OF AI-ASSISTED CAPSULE ENDOSCOPY: A COMPARISON BETWEEN EXPERTS AND TRAINEES INAN 80-CASE SERIES Boc.02.1人工智能辅助胶囊内窥镜的诊断率：80例专家与学员的比较

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-04-01 DOI: 10.1016/S1590-8658(25)00345-7

E. Tettoni, S. Piccirelli, C. Ferrari, D. Salvi, N. Belluardo, E.V. Pesatori, C. Marmo, P. Cesaro, C. Spada

引用次数: 0

OC.04.9 OPTIMIZING CA19.9 ROLE IN BD-IPMN SURVEILLANCE: ENHANCED VALUE OF NEW THRESHOLDS 0.04.9优化ca19.9在bd-ipmn监测中的作用：提高新阈值

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-04-01 DOI: 10.1016/S1590-8658(25)00417-7

S. Kayali, E. Marabotto, S. Dibitetto, A. Busatto, S. Chierici, S. Caprioli, A.P. Luzzi, S. Fantasia, F. Gaiani, E. Savarino, L. Laghi, C.G. De Angelis, E.G. Giannini

引用次数: 0